ARTICLE | Deals
Pfizer Inc. (NYSE:PFE) paying $1.25 billion to license ex-China rights to a PD-1 x VEGF therapy from 3SBio Inc. (HKEX:1530) remained the biggest deal of the past week, but a handful of other transactions shared the spotlight — including two molecular glue partnerships.
In a May 21 deal worth $105 million up front, molecular glue company Orionis Biosciences Inc. announced a second multiyear collaboration with the Genentech unit of Roche (SIX:ROG; OTCQB:RHHBY). Their first partnership centered on targeted protein degraders for cancer and neurology, while this second one focuses on non-degrading molecular glues for cancer...